Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
374 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Schizophrenia - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Schizophrenia - Pipeline Review, H2 2015', provides an overview of the Schizophrenia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Schizophrenia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Schizophrenia Overview 7 Therapeutics Development 8 Schizophrenia - Therapeutics under Development by Companies 10 Schizophrenia - Therapeutics under Investigation by Universities/Institutes 17 Schizophrenia - Pipeline Products Glance 18 Schizophrenia - Products under Development by Companies 22 Schizophrenia - Products under Investigation by Universities/Institutes 30 Schizophrenia - Companies Involved in Therapeutics Development 31 Schizophrenia - Therapeutics Assessment 107 Drug Profiles 124 Schizophrenia - Recent Pipeline Updates 280 Schizophrenia - Dormant Projects 334 Schizophrenia - Discontinued Products 347 Schizophrenia - Product Development Milestones 352 Appendix 358
List of Tables
Number of Products under Development for Schizophrenia, H2 2015 23 Number of Products under Development for Schizophrenia - Comparative Analysis, H2 2015 24 Number of Products under Development by Companies, H2 2015 26 Number of Products under Development by Companies, H2 2015 (Contd..1) 27 Number of Products under Development by Companies, H2 2015 (Contd..2) 28 Number of Products under Development by Companies, H2 2015 (Contd..3) 29 Number of Products under Development by Companies, H2 2015 (Contd..4) 30 Number of Products under Development by Companies, H2 2015 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H2 2015 32 Comparative Analysis by Late Stage Development, H2 2015 33 Comparative Analysis by Clinical Stage Development, H2 2015 34 Comparative Analysis by Early Stage Development, H2 2015 35 Comparative Analysis by Unknown Stage Development, H2 2015 36 Products under Development by Companies, H2 2015 37 Products under Development by Companies, H2 2015 (Contd..1) 38 Products under Development by Companies, H2 2015 (Contd..2) 39 Products under Development by Companies, H2 2015 (Contd..3) 40 Products under Development by Companies, H2 2015 (Contd..4) 41 Products under Development by Companies, H2 2015 (Contd..5) 42 Products under Development by Companies, H2 2015 (Contd..6) 43 Products under Development by Companies, H2 2015 (Contd..7) 44 Products under Investigation by Universities/Institutes, H2 2015 45 Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc., H2 2015 46 Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc., H2 2015 47 Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H2 2015 48 Schizophrenia - Pipeline by AgeneBio Inc., H2 2015 49 Schizophrenia - Pipeline by Alkermes Plc, H2 2015 50 Schizophrenia - Pipeline by Amgen Inc., H2 2015 51 Schizophrenia - Pipeline by Angita B.V., H2 2015 52 Schizophrenia - Pipeline by ANP Technologies, Inc., H2 2015 53 Schizophrenia - Pipeline by Astellas Pharma Inc., H2 2015 54 Schizophrenia - Pipeline by Athersys, Inc., H2 2015 55 Schizophrenia - Pipeline by BCWorld Pharm Co. Ltd., H2 2015 56 Schizophrenia - Pipeline by BioCrea GmbH, H2 2015 57 Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H2 2015 58 Schizophrenia - Pipeline by Braeburn Pharmaceuticals, Inc., H2 2015 59 Schizophrenia - Pipeline by Catalyst Biosciences, Inc., H2 2015 60 Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H2 2015 61 Schizophrenia - Pipeline by Curemark, LLC, H2 2015 62 Schizophrenia - Pipeline by Delpor, Inc., H2 2015 63 Schizophrenia - Pipeline by Dong Wha Pharma Co., Ltd., H2 2015 64 Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H2 2015 65 Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H2 2015 66 Schizophrenia - Pipeline by Eli Lilly and Company, H2 2015 67 Schizophrenia - Pipeline by Evotec AG, H2 2015 68 Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 69 Schizophrenia - Pipeline by FORUM Pharmaceuticals Inc., H2 2015 70 Schizophrenia - Pipeline by Galenea Corp., H2 2015 71 Schizophrenia - Pipeline by GeNeuro SA, H2 2015 72 Schizophrenia - Pipeline by Genovate Biotechnology Co., LTD., H2 2015 73 Schizophrenia - Pipeline by Gilead Sciences, Inc., H2 2015 74 Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015 75 Schizophrenia - Pipeline by GP Pharm, S.A., H2 2015 76 Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H2 2015 77 Schizophrenia - Pipeline by H. Lundbeck A/S, H2 2015 78 Schizophrenia - Pipeline by Heptares Therapeutics Limited, H2 2015 79 Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2015 80 Schizophrenia - Pipeline by Indivior Plc, H2 2015 81 Schizophrenia - Pipeline by INSYS Therapeutics, Inc., H2 2015 82 Schizophrenia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2015 83 Schizophrenia - Pipeline by IntelGenx Corp., H2 2015 84 Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 85 Schizophrenia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2015 86 Schizophrenia - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H2 2015 87 Schizophrenia - Pipeline by Johnson & Johnson, H2 2015 88 Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H2 2015 89 Schizophrenia - Pipeline by KemPharm, Inc., H2 2015 90 Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2015 91 Schizophrenia - Pipeline by Lead Discovery Center GmbH, H2 2015 92 Schizophrenia - Pipeline by Lohocla Research Corporation, H2 2015 93 Schizophrenia - Pipeline by Luye Pharma Group Ltd., H2 2015 94 Schizophrenia - Pipeline by Merck & Co., Inc., H2 2015 95 Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 96 Schizophrenia - Pipeline by Neuralstem, Inc., H2 2015 97 Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H2 2015 98 Schizophrenia - Pipeline by NeurOp, Inc, H2 2015 99 Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H2 2015 100 Schizophrenia - Pipeline by Omeros Corporation, H2 2015 101 Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 102 Schizophrenia - Pipeline by Peptron, Inc., H2 2015 103 Schizophrenia - Pipeline by Pfizer Inc., H2 2015 104 Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H2 2015 105 Schizophrenia - Pipeline by PsychoGenics, Inc., H2 2015 106 Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H2 2015 107 Schizophrenia - Pipeline by Richter Gedeon Nyrt., H2 2015 108 Schizophrenia - Pipeline by Saniona AB, H2 2015 109 Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 110 Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 111 Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015 112 Schizophrenia - Pipeline by Suven Life Sciences Ltd., H2 2015 113 Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2015 114 Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 115 Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H2 2015 116 Schizophrenia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 117 Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H2 2015 118 Schizophrenia - Pipeline by XTL Biopharmaceuticals Ltd., H2 2015 119 Schizophrenia - Pipeline by Zogenix, Inc., H2 2015 120 Schizophrenia - Pipeline by Zysis Limited, H2 2015 121 Assessment by Monotherapy Products, H2 2015 122 Assessment by Combination Products, H2 2015 123 Number of Products by Stage and Target, H2 2015 125 Number of Products by Stage and Mechanism of Action, H2 2015 131 Number of Products by Stage and Route of Administration, H2 2015 136 Number of Products by Stage and Molecule Type, H2 2015 138 Schizophrenia Therapeutics - Recent Pipeline Updates, H2 2015 295 Schizophrenia - Dormant Projects, H2 2015 349 Schizophrenia - Dormant Projects (Contd..1), H2 2015 350 Schizophrenia - Dormant Projects (Contd..2), H2 2015 351 Schizophrenia - Dormant Projects (Contd..3), H2 2015 352 Schizophrenia - Dormant Projects (Contd..4), H2 2015 353 Schizophrenia - Dormant Projects (Contd..5), H2 2015 354 Schizophrenia - Dormant Projects (Contd..6), H2 2015 355 Schizophrenia - Dormant Projects (Contd..7), H2 2015 356 Schizophrenia - Dormant Projects (Contd..8), H2 2015 357 Schizophrenia - Dormant Projects (Contd..9), H2 2015 358 Schizophrenia - Dormant Projects (Contd..10), H2 2015 359 Schizophrenia - Dormant Projects (Contd..11), H2 2015 360 Schizophrenia - Dormant Projects (Contd..12), H2 2015 361 Schizophrenia - Discontinued Products, H2 2015 362 Schizophrenia - Discontinued Products (Contd..1), H2 2015 363 Schizophrenia - Discontinued Products (Contd..2), H2 2015 364 Schizophrenia - Discontinued Products (Contd..3), H2 2015 365 Schizophrenia - Discontinued Products (Contd..4), H2 2015 366
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
